SAN DIEGO–(BUSINESS WIRE)–Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2022 and updated its financial guidance for the year ending December 31, 2022.
Third Quarter 2022 Financial Highlights Compared to Third Quarter 2021:
Recent Strategic Highlights:
“More than 400,000 people worldwide have chosen Tandem and the t:slim X2 insulin pump for their therapy needs, and broad feedback from clinicians supports that we are leading in automated insulin dosing with our Control-IQ technology,” said John Sheridan, president and chief executive officer. “We are committed to expanding our portfolio of diabetes solutions to drive longer-term growth and leverage our operations, as we continue our work to improve the lives of people with diabetes.”
Third Quarter 2022 Financial Results Compared to Third Quarter 2021
Starting with the third quarter 2022, the Company is providing more expansive financial results on both a GAAP and non-GAAP basis as detailed in Table E.
See tables for additional financial information.
2022 Annual Guidance Update
“In this highly variable environment, we are factoring greater caution into our guidance to re-baseline expectations for the next few quarters,” said Leigh Vosseller, executive vice president and chief financial officer. “The timing of our potential new product introductions next year adds increased complexity to the current market dynamics, so we feel it’s prudent for our guidance to reflect more moderate growth in periods between new product launches.”
For the year ending December 31, 2022, the Company is updating its financial guidance as follows:
* See Table E for reconciliation of non-GAAP financial measures
Non-GAAP Financial Measures
Certain non-GAAP financial measures are presented in this press release, including non-GAAP sales, non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating loss, non-GAAP net loss, EBITDA and adjusted EBITDA, as well as adjusted EBITDA margin, to provide information that may assist investors in understanding the Company’s financial results and assessing its prospects for future performance. The Company believes these non-GAAP financial measures are important operating performance indicators because they exclude items that are unrelated to, and may not be indicative of, the Company’s core operating results. These non-GAAP financial measures, as calculated, may not necessarily be comparable to similarly titled measures of other companies and may not be appropriate measures for comparing the performance of other companies relative to the Company. These non-GAAP financial results are not intended to represent, and should not be considered to be more meaningful measures than, or alternatives to, measures of operating performance as determined in accordance with GAAP. To the extent the Company utilizes such non-GAAP financial measures in the future, they will be calculated using a consistent method from period to period. A reconciliation of each of the GAAP financial measures to the most directly comparable non-GAAP financial measures has been provided under the heading “Reconciliation of GAAP versus Non-GAAP Financial Results” in the financial statement tables attached to this press release. Consistent with SEC regulations, the Company has not provided a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures in reliance on the “unreasonable efforts” exception set forth in the applicable regulations, because there is substantial uncertainty associated with predicting any future adjustments that may be made to the Company’s GAAP financial measures in calculating the non-GAAP financial measures.
Conference Call
The Company will hold a conference call and simultaneous webcast today at 4:30pm Eastern Time (1:30pm Pacific Time). The link to the webcast will be available by accessing the Events & Presentations tab in the Investor Center of the Tandem Diabetes Care website at http://investor.tandemdiabetes.com, and will be archived for 30 days. To access the call by phone, please use this link (https://register.vevent.com/register/BIcb637284625c45fcbca173def3f7fc70) and you will be provided with dial-in details, including a personal pin.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a global insulin delivery and diabetes technology company based in San Diego, California, creates new possibilities for people living with diabetes, their loved ones, and healthcare providers through a positively different experience. The Company’s human-centered approach to design, development, and support delivers innovative products and services for people who use insulin. Tandem manufactures and sells the t:slim X2 insulin pump with Control-IQ technology. For more information, visit tandemdiabetes.com.
Tandem Diabetes Care is a registered trademark and t:slim X2 and Control-IQ are trademarks of Tandem Diabetes Care, Inc.
Follow Tandem Diabetes Care on Twitter @tandemdiabetes; use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at https://www.linkedin.com/company/tandemdiabetes.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. These forward-looking statements include statements regarding, among other things, the Company’s projected financial results. The Company’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties. For instance, the Company’s ability to achieve projected financial results will be impacted by market acceptance of the Company’s existing products and products under development by physicians and people with diabetes; the Company’s ability to establish and sustain operations to support international sales, including expansion into additional geographies; changes in reimbursement rates or insurance coverage for the Company’s products; the Company’s ability to meet increasing operational and infrastructure requirements from higher customer interest and a larger base of existing customers; the Company’s ability to complete the development and launch of new products when anticipated; the potential that newer products, or other technological breakthroughs for the monitoring, treatment or prevention of diabetes, may render the Company’s products obsolete or less desirable; the depth and duration of the evolving COVID-19 pandemic, and the global response thereto; reliance on third-party relationships, such as outsourcing and supplier arrangements; global economic conditions; and other risks identified in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and other documents that the Company files with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events or other factors.
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
Table A
(in thousands)
September 30,
December 31,
2022
2021
Assets
(Unaudited)
Current assets:
Cash, cash equivalents and short-term investments
$
608,727
$
623,811
Accounts receivable, net
112,805
110,725
Inventories
104,774
68,551
Other current assets
7,997
8,433
Total current assets
834,303
811,520
Property and equipment, net
72,905
50,386
Operating lease right-of-use assets
116,474
27,503
Other long-term assets
23,838
15,728
Total assets
$
1,047,520
$
905,137
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable, accrued expenses and employee-related liabilities
$
117,396
$
89,007
Operating lease liabilities
12,120
9,279
Deferred revenue
12,974
10,182
Other current liabilities
31,140
23,388
Total current liabilities
173,630
131,856
Convertible senior notes, net – long-term
282,787
281,467
Operating lease liabilities – long-term
127,109
23,922
Deferred revenue – long-term
19,143
16,940
Other long-term liabilities
23,029
17,840
Total liabilities
625,698
472,025
Total stockholders’ equity
421,822
433,112
Total liabilities and stockholders’ equity
$
1,047,520
$
905,137
TANDEM DIABETES CARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Table B
(in thousands, except per share data)
(Unaudited)
Three Months Ended September 30,
Nine Months Ended September 30,
2022
2021
2022
2021
Sales
$
204,547
$
179,627
$
580,716
$
492,803
Cost of sales
100,122
82,882
283,252
230,317
Gross profit
104,425
96,745
297,464
262,486
Operating expenses:
Selling, general and administrative
84,104
64,923
237,989
190,009
Research and development
36,798
24,102
103,529
62,562
Acquired in-process research and development expenses
31,016
—
31,016
—
Total operating expenses
151,918
89,025
372,534
252,571
Operating income (loss)
(47,493
)
7,720
(75,070
)
9,915
Total other income (expense), net
144
(1,872
)
(1,668
)
(5,159
)
Income (loss) before income taxes
(47,349
)
5,848
(76,738
)
4,756
Income tax expense (benefit)
1,621
54
2,003
(2
)
Net income (loss)
$
(48,970
)
$
5,794
$
(78,741
)
$
4,758
Net income (loss) per share, basic
$
(0.76
)
$
0.09
$
(1.23
)
$
0.08
Net income (loss) per share, diluted
$
(0.76
)
$
0.09
$
(1.23
)
$
0.07
Weighted average shares used to compute basic net income (loss) per share
64,236
63,167
64,066
62,780
Weighted average shares used to compute diluted net income (loss) per share
64,237
64,784
64,067
64,198
TANDEM DIABETES CARE, INC.
SALES BY GEOGRAPHY
Table C
(Unaudited)
($’s in thousands)
Three Months Ended September 30,
Nine Months Ended September 30,
2022
2021
% Change
2022
2021
% Change
United States:
Pump(1)
$
80,696
$
78,771
2
%
$
235,849
$
221,724
6
%
Infusion sets
44,839
37,725
19
%
128,490
97,251
32
%
Cartridges
20,122
16,289
24
%
57,502
44,136
30
%
Other
378
321
18
%
1,144
914
25
%
Total Sales in the United States(1)
$
146,035
$
133,106
10
%
$
422,985
$
364,025
16
%
Outside the United States:
Pump
$
27,385
$
23,762
15
%
$
75,515
$
70,300
7
%
Infusion sets
21,964
16,175
36
%
57,258
41,074
39
%
Cartridges
8,996
6,269
43
%
24,539
16,878
45
%
Other
167
315
(47
)%
419
526
(20
)%
Total Sales Outside the United States
$
58,512
$
46,521
26
%
$
157,731
$
128,778
22
%
Total Worldwide Sales(1)
$
204,547
$
179,627
14
%
$
580,716
$
492,803
18
%
1)
Reduced by $0.6 million associated with the Tandem Choice technology access program during the three and nine months ended September 30, 2022.
TANDEM DIABETES CARE, INC.
PUMP SHIPMENTS
Table D
Three Months Ended September 30,
Nine Months Ended September 30,
2022
2021
% Change
2022
2021
% Change
Pumps Shipped:
United States
20,394
20,296
0
%
59,870
57,605
4
%
Outside the United States
12,113
11,262
8
%
32,846
33,122
(1
)%
Total Pumps Shipped
32,507
31,558
3
%
92,716
90,727
2
%
TANDEM DIABETES CARE, INC.
Reconciliation of GAAP versus Non-GAAP Financial Results (Unaudited)
Table E
($’s in thousands)
Three Months Ended September 30,
Nine Months Ended September 30,
2022
2021
2022
2021
GAAP sales
$
204,547
$
179,627
$
580,716
$
492,803
Adjustments for Tandem Choice (1)
599
—
599
—
Non-GAAP sales
$
205,146
$
179,627
$
581,315
$
492,803
GAAP gross profit
$
104,425
$
96,745
$
297,464
$
262,486
Adjustments for Tandem Choice(1)
599
—
599
—
Non-GAAP gross profit
$
105,024
$
96,745
$
298,063
$
262,486
Non-GAAP gross margin(3)
51
%
54
%
51
%
53
%
GAAP operating income (loss)
$
(47,493
)
$
7,720
$
(75,070
)
$
9,915
Acquired in-process research and development(2)
31,016
—
31,016
—
Adjustments for Tandem Choice(1)
599
—
599
—
Non-GAAP operating income (loss)
$
(15,878
)
$
7,720
$
(43,455
)
$
9,915
Non-GAAP operating margin(3)
(8
) %
4
%
(7
) %
2
%
GAAP net income (loss)
$
(48,970
)
$
5,794
$
(78,741
)
$
4,758
Income tax expense (benefit)
1,621
54
2,003
(2
)
Interest income and other, net
(1,708
)
(31
)
(2,858
)
(721
)
Interest expense
1,576
1,511
4,629
4,526
Depreciation and amortization
3,508
3,400
10,689
10,325
EBITDA
(43,973
)
10,728
(64,278
)
18,886
Change in fair value of common stock warrants
(12
)
392
(103
)
1,354
Stock-based compensation expense
22,236
15,729
60,477
43,653
Acquired in-process research and development(2)
31,016
—
31,016
—
Adjustments for Tandem Choice(1)
599
—
599
—
Adjusted EBITDA
$
9,866
$
26,849
$
27,711
$
63,893
Adjusted EBITDA Margin(3)
5
%
15
%
5
%
13
%
GAAP net income (loss)
$
(48,970
)
$
5,794
$
(78,741
)
$
4,758
Acquired in-process research and development(2)
31,016
—
31,016
—
Adjustments for Tandem Choice(1)
599
—
599
—
Non-GAAP net income (loss)
$
(17,355
)
$
5,794
$
(47,126
)
$
4,758
(1)
In September 2022, the Company launched Tandem Choice to provide in-warranty eligible t:slim X2 customers a path towards ownership of the next generation hardware platform for a fee when available. The accounting treatment for Tandem Choice has a high degree of complexity, initially requiring the deferral of some portion of sales for shipments of eligible pumps.
(2)
The Company recorded a $31.0 million charge representing the value of acquired in-process research and development assets with no alternative future use, and acquisition related expenses.
(3)
Non-GAAP margins including non-GAAP gross margin, non-GAAP operating margin, and adjusted EBITDA margin are calculated using non-GAAP sales.
Media Contact:
858-255-6388
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com
Media Contact:
858-255-6388
media@tandemdiabetes.com
Investor Contact:
858-366-6900
IR@tandemdiabetes.com